Is NCT07005050 recruiting in Las Vegas, NV?

Yes, NCT07005050 is currently recruiting participants at its Las Vegas, NV location. This uncontrolled hypertension clinical trial is actively enrolling qualified participants.

How do I join the uncontrolled hypertension clinical trial in Las Vegas?

To join this clinical trial in Las Vegas, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Las Vegas clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Uncontrolled Hypertension Clinical Trial in Las Vegas, NV

About This Uncontrolled Hypertension Study in Las Vegas

The RPD Pilot trial will evaluate the safety and effectiveness of Verve Medical's RPDTM renal denervation system for hypertensive patients with uncontrolled blood pressure despite use of two medications at a therapeutic dose. The novelty of the RPDTM system relates to its placement via natural orifice into the renal pelvis (bilaterally) for delivery of radiofrequency energy to ablate the nerves that pass through the outer wall of the renal pelvis, a technique referred to as renal pelvic denervation (RPD).

Sponsor: Verve Medical, Inc

Who Can Participate

Inclusion Criteria

Currently taking 2 anti-hypertensive medications (NOTE: no changes to medications allowed until after 2-month primary endpoint). \- As recommended in ACC/AHA 2017 Guideline,2 subjects are to be taking one anti-hypertensive antagonizing the renin-angiotensin system, including ACE inhibitor, ARB or renin inhibitor. Second drug should either be a calcium channel blocker (amlodipine preferred) or a thiazide diuretic.

Stable antihypertensive medical regimen for at least 30 days.

Ambulatory mean daytime SBP ≥135 mmHg.

Ambulatory daytime SBP \<170 and DBP \<105 mmHg.

Office systolic SBP ≥140 mmHg and \<180.

Exclusion Criteria

History of non-compliance with medical care or medical treatments.

History of atrial fibrillation.

Pregnant (verified with a urine or blood pregnancy test), breast-feeding, or planning to become pregnant. Note that all premenopausal women will be screened for pregnancy (see section 4.7.4).

Office SBP ≥180 and DBP ≥110 mmHg.

Untreated urinary tract infection.

Renal collecting system is compromised, such that the subject cannot undergo routine cystoscopy and retrograde pyelogram, as exemplified by duplicated collecting system, i.e., two or more ipsilateral ureters.

Pre-existing hydronephrosis, presence of renal calculi or ectopic, pelvic or ptotic kidney(s).

Receiving dialysis treatment.

Renal transplant recipient.

Presence of only one kidney, or patients with dominant unilateral kidney function with one kidney split function less than 35%

Polycystic kidney disease.

Diabetes treated with SGLT2 inhibitor and/or GLP-1 agonist

Persistent albuminuria (urine with 30-300 mg albumin/g creatinine)

Focal sclerosing glomerulosclerosis.

On any of the following medications: clonidine, guanfacine, or methyldopa.

Known secondary causes of hypertension such as adrenal disease, renal artery stenosis, renovascular hypertension.

Evidence in medical history or at screening of hyperaldosteronism, defined as aldosterone/renin activity \> 30 or aldosterone level \>15 ng/dL

Glomerulonephritis or interstitial nephritis or eGFR \<45 ml/min/1.73m2.

Type I diabetes mellitus.

Stenotic valvular heart disease for which reduction of blood pressure would be hazardous.

One or more episodes of orthostatic hypotension within the prior 6 months defined in section 6.6.2 as reduction of systolic blood pressure of ≥20 mmHg or diastolic blood pressure of ≥10 mm Hg within 3 minutes of standing.

Myocardial infarction, unstable angina, or stroke in the prior 6 months.

History of symptomatic heart failure

Echocardiographic evidence of dilated, infiltrative or hypertrophic cardiomyopathy or intracardiac mass.

Surgically correctable valvular heart disease.

Peripheral arterial disease manifest clinically by claudication or non-healing ulcers.

Any medical condition (including psychiatric disease) that would interfere with conducting the study or would not be in the best interest of the subject.

Prior diagnosis of pulmonary hypertension, use of chronic oxygen therapy or need for mechanical ventilation

Presence of severe obstructive sleep apnea not treated adequately by CPAP at screening.

On medications that affect blood pressure through off target effects, e.g., NSAIDs, steroids etc.

Uncorrected bleeding diathesis

Any clinical condition that can affect blood pressure or require the use of medications that can affect blood pressure (e.g., NSAIDs, steroids, cold remedies).

Life expectancy \< 24 months for any reason (investigator determination).

Works night shifts.

Upper arm circumference \> 20".

Subjects currently enrolled in another hypertension trial.

Subjects who previously received device therapy for hypertension, including renal denervation.

Subjects with a history of recurrent renal stones including episodes within the prior 6 months (subjects with first diagnosis of asymptomatic renal stone(s) at baseline/screening can be treated and rescreened at least one week following successful therapy of nephrolithiasis).

History of narcotic / opiate drug abuse

History of chronic pain syndrome receiving ongoing therapy with narcotic and/or opiate therapy

Active uroepithelial cancer

Artificial urinary sphincter or penile prosthesis implanted.

Planned medical procedures that could potentially interfere with measurement of blood pressure or assessment of any safety/effectiveness endpoints within 12 months of randomization

Conditions that could potentially interfere with accuracy of blood pressure measurements

Vulnerable subject populations (e.g., incarcerated or cognitively challenged adults).

Pre-existing urological abnormalities such as hydronephrosis, ureteral vesicular reflux (congenital or acquired), neoplasia, etc.

Urinary tract anomalies or primary (FSGS) or secondary (e.g., Diabetic nephropathy) renal disease

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Las Vegas?

Yes, this clinical trial (NCT07005050) has an active research site in Las Vegas, NV that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Uncontrolled Hypertension Treatment Options in Las Vegas, NV

If you're searching for uncontrolled hypertension treatment options in Las Vegas, NV, this clinical trial (NCT07005050) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Las Vegas research site is actively enrolling participants for this clinical trial. You'll receive care from experienced uncontrolled hypertension specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all uncontrolled hypertension clinical trials near you to find additional studies recruiting in your area.

Uncontrolled Hypertension Clinical Trial in Las Vegas, NV

Expert Care in Las Vegas

IRB Approved

No-Cost Care

Apply for This Las Vegas Location

Why Participate?

Simple Process